Microbix Biosystems Inc.
341 Bering Avenue
228 articles with Microbix Biosystems Inc.
Meetings with Growth-Oriented Investors, September 27-29, 2019
Four IVD Controls to Support Performance of Human Papilloma Virus Tests
Microbix Biosystems Inc. reports results for its third quarter and nine months of fiscal 2019, the three-month and nine-month periods ending June 30, 2019 ("Q3" & "YTD"), with record YTD sales, strong YTD sales growth, improving percentage gross margin, and progress on its strategic goals.
Largest Customer Confirms Conversion Timetable & Provides Full-Scale Order
Contribution of $2.75 Million to Scale-up, Meet Demand, and Create Highly-Skilled Jobs
Record Sales of $4.25 Million, Sales Growth of 42%, and Material Net Earnings
Healthcare Investor Conference in Toronto on April 30 & May 1
Ken Hughes Appointed COO, Kathryn Froh Retiring
Microbix Biosystems Inc., an innovator of biological products and technologies, announces the voting results from the Annual Meeting of Shareholders which was held on March 27, 2019.
Microbix Biosystems Inc., an innovator of biological products and technologies, announces the issuance of stock options under its shareholder-approved 2018 stock option plan, as part of its compensation programs to incentivize and retain its board of directors, executives, and managers.
Microbix Biosystems Inc. reports results for its first quarter of fiscal 2019, the three-month period ending December 31, 2018 ("Q1"), with lower sales, improving percentage gross margin, improving and positive cash flow from operations and progress toward its operational goals.
New Customers, More Products, and Expanding Capacity
ISO 13485:2016 Medical Devices Certification Attained
Recognized with 2018 Business Innovation Award by MBOT
Showcasing Antigen and Quality Assessment Products
Conference Introduces Growth Companies to Investor September 28-30, 2018
Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products and technologies, reports financial results for its third quarter of fiscal 2018, the three-month period ending June 30, 2018 ("Q3"), with record sales and progress toward its operational goals.
Total Q1 revenue was $2,885,567, an increase of 48% compared to the first quarter of fiscal 2017.
In 2017, the Company achieved a number of notable milestones, including attaining record sales of over $10 million.